Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population
Not Applicable
Completed
- Conditions
- Alzheimer DiseaseParkinson Disease
- Registration Number
- NCT04322461
- Lead Sponsor
- Université de Sherbrooke
- Brief Summary
A two months intervention in which two groups of cognitive disorders, Parkinson and Alzheimer's disease, will receive 50g/day of a commercial MCT supplement combined with supervised aerobic exercise 3 times/week. Cognition and ketones will be assess before and after the intervention, along with endocannabinoids plasma concentrations.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
- Alzheimer's or parkinson disease diagnostic
- Stable medication associated with the disease
- Able to consent
- Presence of an accompanying person for the first and last visit.
- Ability to read and talk in French
Exclusion Criteria
- MMSE < 20
- MCT or coconut oil supplementation
- Coconut allergy
- Cannabis, THC or CBD consumption
- Excessive alcohol consumption
- Physical activity 3x/week
- Presence of an metallic object in the body
- Impossibility to lay in dorsal decubitus for 40 minutes
- Cardiac disease
- Any uncontrolled disease that could interfer with the project.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Cognition 2 months, evaluation before and after intervention Measure of cognition with CANTAB
Ketones 2 months, evaluation before and after intervention Measurement of ketones concentrations
- Secondary Outcome Measures
Name Time Method Endocannabinoids 2 months, evaluation before and after intervention Endocannabinoids plasma concentration
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link MCT supplementation and aerobic exercise to cerebral metabolism in Parkinson and Alzheimer's disease?
How does the combination of MCTs and aerobic exercise compare to standard-of-care treatments for cognitive decline in Parkinson and Alzheimer's populations?
Which endocannabinoid biomarkers are associated with improved cognitive outcomes following MCT and exercise intervention in NCT04322461?
What adverse events are reported with Betaquik MCT supplementation in neurodegenerative disease trials and how are they managed?
Are there synergistic effects between ketone metabolism and endocannabinoid signaling in neurodegenerative disorders like Parkinson and Alzheimer's disease?
Trial Locations
- Locations (1)
Centre de recherche sur le vieillissement
🇨🇦Sherbrooke, Quebec, Canada
Centre de recherche sur le vieillissement🇨🇦Sherbrooke, Quebec, Canada